"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

The therapeutic landscape has evolved rapidly with the introduction of biologics and advanced targeted therapies. Yet many inflammatory dermatoses share overlapping cytokine and receptor pathways, supporting the continued need for broader-acting anti-inflammatory options. The enduring clinical utility of the term “steroid-responsive dermatoses” reflects this shared biology.

At the same time, heightened concerns about long-term corticosteroid exposure (“steroid phobia”) have intensified interest in effective, nonsteroidal alternatives. Phosphodiesterase 4 (PDE4) inhibition has emerged as a promising strategy that sits at the nexus of multiple inflammatory pathways, offering the potential to define a new category of “PDE4 inhibitor-responsive dermatoses,” as introduced in a recent paper published in the Journal of Clinical and Aesthetic Dermatology.¹

Mechanistic Rationale for PDE4 Inhibition

PDE4 is a key regulator of intracellular cyclic adenosine monophosphate (cAMP) and is expressed in many immune and inflammatory cells, including T cells, monocytes, dendritic cells, neutrophils, and eosinophils. When overactive, PDE4 lowers cAMP levels, amplifying pro-inflammatory cytokine production. Inhibiting PDE4 elevates cAMP and modulates a broad array of downstream pathways, resulting in decreased inflammatory cytokine release, reduced activation of sensory itch neurons, normalization of keratinocyte differentiation, and, in some studies, enhanced melanocyte survival and melanogenic signaling. The enzyme’s central role across these systems provides biological plausibility for a unifying therapeutic category in which multiple dermatoses improve through PDE4 pathway modulation.

Approved PDE4 Inhibitors

• Apremilast, an oral small-molecule PDE4 inhibitor, is FDA approved for plaque psoriasis (including pediatric indications), psoriatic arthritis, and Behçet’s disease. Randomized controlled trials demonstrate PASI-75 response rates as high as 41% at 16 weeks and sustained long-term benefit. While apremilast’s efficacy is established, twice-daily dosing, gastrointestinal adverse events, weight loss, and rare mood-related events can limit adherence. Nonetheless, apremilast remains a valuable systemic nonbiologic option, particularly for patients who are not candidates for biologic therapy.
• Crisaborole is a topical PDE4 inhibitor approved for mild-to-moderate atopic dermatitis (AD) in adults and children aged ≥3 months. In pooled analyses, crisaborole improves pruritus, global assessments, EASI scores, and quality-of-life measures with a safety profile similar to vehicle. Long-term studies up to 52 weeks show continued efficacy and low rates of serious adverse events. Local stinging or burning, however, appears more common in real-world practice than in clinical trials. As a nonsteroidal option suitable for all ages, crisaborole supports long-term disease control without corticosteroid exposure.
• Roflumilast is available in cream and foam formulations approved for psoriasis, AD, and seborrheic dermatitis. Once-daily dosing improves convenience and adherence. Across phase 2 and 3 trials, roflumilast has demonstrated high rates of IGA success and PASI-75, rapid improvement in seborrheic dermatitis, and strong tolerability, with <2% of patients reporting stinging or burning. Its approval for intertriginous areas further broadens clinical applicability. Oral roflumilast shows promising psoriasis efficacy but is limited by gastrointestinal adverse events.

Expanding Indications

A growing body of literature, ranging from case reports to controlled trials, suggests that additional inflammatory dermatoses may benefit from PDE4 inhibition. These include chronic hand eczema, prurigo nodularis, lichen planus, discoid lupus erythematosus, and vitiligo. While evidence quality varies, the breadth of reported responses underscores PDE4’s central role in cutaneous inflammation and supports further investigation into expanded indications.

The Emerging Framework

Given shared mechanistic pathways and accumulating clinical evidence, the concept of “PDE4 inhibitor-responsive dermatoses” parallels the long-standing category of steroid-responsive disease. PDE4 inhibitors offer several advantages:

• A nonsteroidal mechanism appropriate for chronic use
• Safety in adults and children, including infants (depending on formulation)
• Suitability for sensitive areas such as the face, eyelids, genitals, and flexures
• Utility in conditions with overlapping or unclear inflammatory drivers

As patient hesitancy toward long-term corticosteroid use continues to rise, PDE4 inhibitors provide a compelling alternative or complement to corticosteroids, especially for chronic disease management. Corticosteroids remain appropriate for acute inflammatory flares, but PDE4 inhibitors are increasingly positioned as safe, effective, versatile agents for long-term control.

Conclusion

The concept of PDE4 inhibitor-responsive dermatoses may be “a useful, modern way of thinking about many of the common inflammatory skin conditions that are seen in dermatology each day,” according to the paper authors. This evolving framework may ultimately reshape how dermatologists approach inflammatory skin disease and tailor treatment strategies for diverse patient populations.

Reference

1. Chau C, Baldwin H, Del Rosso J, et al. PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology. J Clin Aesthet Dermatol. 2025;18(12):50–65. https://jcadonline.com/pde4-inhibitor-responsive-dermatoses/#:~:text=Given%20the%20role%20of%20PDE4,of%20the%20common%20inflammatory%20skin